Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Greenhaven Road Capital. This analysis is provided for institutional research purposes only and is not investment advice.
"Fund declined 12% in Q1 as tariff volatility pressured top holdings PAR, KKR, and Cellebrite. Manager used weakness to add to onshoring beneficiary Lifecore and unrelated names."
Greenhaven Road Capital returned -12% net in Q1 2025, underperforming the Russell 2000 by 2% as top holdings PAR, KKR, and Cellebrite gave back prior outperformance amid tariff-induced volatility. President Trump's Liberation Day tariff policies created significant market disruption through erratic implementation and daily policy changes. The manager believes the administration will moderate toward more reasonable trade policies with moderate tariffs rather than the reciprocal approach initially announced. The fund used market weakness to increase positions in beneficiaries like Lifecore, a domestic drug manufacturer positioned for onshoring trends, and added to unrelated holdings like Vistry Group and Hagerty. KKR faces headwinds from multiple compression and private equity liquidity constraints but continues gathering assets through its diversified platform. The manager maintains conviction in portfolio fundamentals and expects outperformance once markets refocus on individual company prospects rather than macro policy uncertainty. Pro-business policies like deregulation and lower rates could provide a favorable operating environment if trade tensions moderate.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High conviction demonstrated through maintaining concentrated positions during volatility, increasing ownership in Lifecore to nearly 10%, and strong language about portfolio fundamentals. Clear thesis articulation despite macro uncertainty.
Growth Outlook
Manager expresses concern about tariff-induced volatility and trade war risks but believes policies will moderate toward more reasonable approaches. Mixed outlook with cautious optimism about eventual policy normalization.
Risk Appetite
Despite market volatility, manager used weakness to increase positions in Lifecore and add to other holdings. Maintained concentrated positions in top holdings, showing selective risk-taking during market stress.
Capital Deployment
Moderate deployment activity with increased positions in Lifecore, Vistry Group, and Hagerty during market weakness. Selective buying opportunities taken but no major portfolio restructuring mentioned.
Forward Guidance
Manager expresses optimism about returning to fundamentals and expects outperformance once tariff uncertainty subsides. Positive about pro-business policies if trade tensions moderate.
Language Signal
Language shows measured optimism with phrases like 'I like our chances' and 'I look forward to the day when we return to fundamentals.' Balanced tone acknowledging risks while maintaining conviction.
Perceived Risk
Manager acknowledges significant risks from tariff policies, trade war potential, and market volatility. Discusses multiple compression, liquidity constraints, and policy uncertainty as meaningful headwinds.
Opportunity Density
Manager identifies selective opportunities in onshoring beneficiaries and oversold names unrelated to tariffs. Sees buying opportunities created by indiscriminate selling but not broad-based opportunity set.
Time Horizon
Long-term focus evident in maintaining positions through volatility and belief that long-term potential of companies will not be impaired by recent macro events. Patient capital approach with multi-year outlook.
